Goodwin Procter advised STALICLA SA on the deal.STALICLA SA announced its exclusive in-licensing agreement with Novartis to develop mavoglurant as a treatment for substance-use disorder, neurodevelopmental disorders,…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
